Your Stroke / Brain Injury Recovery Starts Here


ARNI home-based training and guidance for your rehab is POWERFUL. Accept no substitute.

To mark 20 years of ARNI: £50 off Full Set of Stroke Rehab 7 DVDs. Click Here to Get Yours!

News

Recent news in stroke rehabilitation highlights advancements like using retro video games for cognitive and motor recovery, new wearable robotic devices to assist with arm and leg movement, and high-intensity walking programs showing promise for improving mobility and quality of life in early stroke patients.

Additionally, new non-invasive techniques such as transcranial magnetic stimulation and transcranial direct current stimulation are being investigated for their potential to enhance motor and language skills.

Retro Video Games: researchers in Sydney are using retro video games like “Foot Tetris” and “Space Invaders” to make rehabilitation fun and effective, helping patients with balance, cognitive reaction times, and complex stepping manoeuvres.

Wearable Robots & Devices: startups and universities are developing wearable robots and connected systems for ankle, foot, and upper limb rehabilitation. These devices, some with embedded electrodes, help retrain the brain and muscle connection by detecting muscle activation and stimulating nerves.

Neurostimulation: clinics and universities are researching non-invasive brain stimulation techniques, such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), to improve motor and language recovery after a stroke.

Your blood type plays a role in more than just transfusions. Recent research suggests it may also influence your risk of developing certain health conditions, including stroke. While it’s not the only factor that matters, understanding the connection between blood type and stroke risk can give you a clearer picture of your overall health.

People with blood type A may face a slightly higher risk of early-onset ischemic stroke. A study published in 2022 in the journal Neurology analyzed genetic data from over 16,000 stroke patients and nearly 600,000 controls. The researchers found that individuals with type A blood were 16% more likely to experience a stroke before the age of 60 compared to those with other types. One reason may involve clotting. People with type A blood tend to have higher levels of a protein called von Willebrand factor, which helps blood clot. While this is important for healing, it can also increase the risk of clot formation in blood vessels, potentially leading to a stroke.

Though type AB is the rarest blood type, some research suggests it may carry one of the highest stroke risks. A 2014 study from the University of Vermont found that individuals with type AB blood had an 83% higher risk of stroke. Furthermore, a protein known as Factor VIII, which plays a role in blood clotting, was determined to account for 60% of the association between type AB blood and stroke risk. The combination of A and B antigens as well as higher clotting factor levels may influence inflammation, vascular function, and the likelihood of blood clots, leading to a heightened stroke risk.

The evidence for blood type B and stroke is less consistent. According to a 2023 meta-analysis that examined 145,000 stroke cases and 2,000,000 controls, there is no significant association between blood type B and ischemic stroke. Other smaller studies have found mixed results, with only weak associations between blood type B and stroke risk..

If you have blood type O, the research is a bit more reassuring. Multiple studies have found that people with type O blood generally have a lower risk of developing blood clots and by extension, a lower risk of ischemic stroke. According to the 2022 study mentioned above, those with type O blood were 12% less likely to experience an early-onset stroke compared to those with other blood types. People with type O blood typically have lower levels of von Willebrand factor and factor VIII, both of which play a role in clotting. While this can lead to slower clotting in injuries, it also seems to provide some protection against unwanted clots in the arteries.

One of the more interesting findings from recent research is that the connection between blood type and stroke risk may be stronger in younger adults. The 2022 Neurology study found that the difference in stroke risk based on blood type was more pronounced in people under 60. This may be because in older adults, other factors, like high blood pressure, atrial fibrillation, and diabetes, play a more dominant role in stroke risk. In younger individuals, genetic and biological differences such as blood type may stand out more clearly.

A new research initiative aims to lay the foundation for the country’s first genetic screening programme for brain aneurysms—potentially reshaping how the NHS identifies and manages a life-threatening but often overlooked condition that can devastate families for generations.

The ROAR-DNA Project, a UK-based multicentre research project bringing together researchers from University Hospital Southampton NHS Foundation Trust (UHS) and the University of Southampton, is the first study of its kind and scale to investigate the genetic markers that may predispose people to develop brain aneurysms.

Brain aneurysms are balloon-like swellings in blood vessels of the brain, found in approximately 3 per cent of the UK population, that’s over 2 million people. While most aneurysms remain stable and harmless, around 1 in 100 will rupture, usually without warning, causing a subarachnoid haemorrhage (SAH)—a type of stroke that can be fatal or severely disabling.

In the UK, an estimated 3,000 to 5,000 people experience a brain aneurysm rupture each year, with around half of these cases proving fatal.

Most aneurysms are sporadic, meaning they are one-off events, but there is evidence of a strong genetic component to the development of intracranial (brain) aneurysms. They often run in families with over 16 per cent of patients with an aneurysm having an affected parent or sibling.

Despite this significant data, no genetic screening programme currently exists, and little is known about the genes that impact aneurysm growth and rupture.

The UK four-year ROAR-DNA Project aims to close that gap by collecting and analysing genetic data from 6,000 patients with brain aneurysms, comparing this against data from patients without brain aneurysms, working in tandem with the existing ROAR Study, which is already tracking over 20,000 patients across the NHS—the largest study of its kind globally.

The deal is that after a stroke or TIA, car (and motorbike) drivers are not allowed drive for a minimum of one calendar month. Some people will be able to drive after the minimum period but others will have to stop for longer; some people will have to stop driving for good. It’s your responsibility to ensure you are safe to drive.

If your doc, therapist or eye specialist thinks you are not safe to drive, you must stop driving and contact the DVLA (if you don’t, you risk being fined up to £1,000). They might ask you to have a driving assessment. But even if nobody tells you to stop driving, it’s your responsibility to find out if you are able to drive after a stroke. This depends on several things including the type of stroke you had, its effects and other medical conditions you may (now) have, like epilepsy.

If think your driving might be affected by stroke, a Driving Mobility centre can give you individual advice. They can tell you if you need to inform the DVLA (or DVA in Northern Ireland), who may arrange a driving assessment and support with going back to driving.

You also have to tell your motor insurance company if you have had a stroke or TIA. If you don’t, your insurance might be invalid. If you drive without insurance, you can be fined or lose your licence.

See the DVLA stroke guidance online or contact DVLA medical enquiries on 0300 790 6806 for advice about the process. Motorists in Northern Ireland can call the DVA on 0300 200 7861 for advice.

The HIT-Stroke Trial 2 RCT is underway (in protocol stage). It examines moderate-intensity exercise versus high-intensity interval training to determine the optimal training intensity for walking rehabilitation in chronic stroke.

Current practice guidelines recommend moderate to vigorous intensity locomotor training to improve walking outcomes in chronic stroke. But these intensities span a wide range, and the lack of specificity may lead to under-dosing or over-dosing of training intensity.

We are sure that you already know that the evidence indicates that vigorous intensity locomotor training improves walking outcomes significantly more than moderate intensity. But previous studies have not been powered to rule out the possibility of meaningful risk increases or negligible benefit with vigorous versus moderate intensity, nor have they been designed to compare sustained effects after training ends.

In this single-blind, 3-site, randomized trial, 156 chronic (>6 months) stroke survivors will be allocated to 36 sessions (3 times a week for 12 weeks) of either high intensity interval or moderate intensity continuous locomotor training. Outcomes are assessed at baseline, after 4 weeks, 8 weeks, 12 weeks (POST), and 3 months after completing training.

The primary outcome is walking capacity (6-minute walk distance). Secondary outcomes include comfortable and fast gait speed, aerobic capacity, fatigue, balance confidence, quality of life, and motivation for exercise. Statistical analyses will compare outcome changes and adverse events between treatment groups, and will include subgrouping by walking limitation severity.

This study by Christine Garrity (Department of Rehabilitation, University of Cincinnati) and colleagues will hopefully provide important new information to guide greater specificity and individualization of locomotor training intensity in chronic stroke.

For millions of women, combined hormonal contraceptives are a part of their daily life – providing a convenient and effective option for preventing pregnancy and managing their menstrual cycle.

But new findings are sounding the alarm on a serious, and often overlooked, risk: stroke.

According to recent findings presented at the European Stroke Organisation Conference, combined oral hormonal contraceptives (which contains both oestrogen and progestogen) may significantly increase the chance of women experiencing a cryptogenic stroke. This is a sudden and serious type of stroke that occurs with no obvious cause.

Surprisingly, in younger adults – particularly women – cryptogenic strokes make up approximately 40% of all strokes. This suggests there may be sex-specific factors which contribute to this risk – such as hormonal contraception use. These recently-presented findings lend themselves to this theory.

At this year’s conference, researchers presented findings from the Secreto study. This is an international investigation that has been conducted into the causes of unexplained strokes in young people aged 18 to 49. The study enrolled 608 patients with cryptogenic ischaemic stroke from 13 different European countries.

One of their most striking discoveries was that women who used combined oral contraceptives were three times more likely to experience a cryptogenic stroke compared to non-users. These results stood, even after researchers adjusted for other factors which may have contributed to stroke risk (such as obesity and history of migraines).

A new campaign by the NHS in England is encouraging people who experience the first sign of a stroke not to delay calling 999, after analysis of calls made in the last year showed the average time to do so was nearly an hour and a half.

England’s most senior doctor says stroke symptoms might not appear obvious or dramatic, but they are always a reason to act quickly.

About 100,000 people have a stroke each year in the UK and more than a third die from related issues, making it the fourth biggest cause of death in the UK.

The most common symptoms are struggling to smile or raise an arm, and slurring words when speaking.

NHS England says recognising any one of these signs in yourself or others and dialling 999 urgently is crucial to getting prompt, specialist treatment.

Yet the average time taken to make that emergency call was 88 minutes in 2023-24, NHS data reveals.

The analysis, from a team at King’s College London, looked at data for more than 41,000 stroke patients who were taken by ambulance to hospital.

NHS England also said a recent poll they carried out found a mistaken belief that two or three stroke symptoms were necessary before calling 999.

‘v-health’ pairs virtual task-based games with Valkyrie’s patented FES wearables with the goal of delivering accessible and measurable upper limb training for stroke survivors to help them regain function and independence.

The combination of immersive XR and neuromuscular stimulation is intended to encourage repetitive movement, assist motor relearning, and support patient engagement. A British technology company has received £500,000 in funding to further develop a neurorehabilitation platform that combines electrical stimulation with virtual reality.

Valkyrie Industries was awarded a grant through the Biomedical Catalyst 2024 competition by Innovate UK, part of UK Research and Innovation (UKRI). The funding will support the continued development of v-health, Valkyrie’s platform designed for neuromuscular rehabilitation using functional electrical stimulation (FES) and extended reality (XR).

The project is backed by King’s College London, Guy’s and St Thomas’ NHS Foundation Trust.

The study will enrol 70 stroke survivors across the Guy’s and St Thomas’ NHS Foundation Trust and the 6 Hobbs Rehabilitation sites in the South West and East. Focusing on individuals across a wide range of stroke recovery with wrist weakness, the research will assess the impact of the v-health platform during motor learning tasks.

Participants with wrist weakness across varying stages of stroke recovery will take part in motor learning exercises using the v-health system. The research aims to evaluate both the effectiveness and practical application of the platform in healthcare settings.

More than 70% of people experiencing stroke suffer upper-limb dysfunction, which can significantly limit independence in daily life. The growing strain on national healthcare resources, coupled with the rising demand for personalised, home-based rehabilitation, along with increased familiarity with digital technologies, has set the stage for developing an advanced therapeutics system consisting of a wearable solution aimed at complementing current stroke rehabilitation to enhance recovery outcomes.

Very long-term friend and supporter of ARNI, Professor Cherry Kilbride , and her colleagues, have developed an advanced prototype integrating electromyography smart sensors, functional electrical stimulation, and virtual reality technologies in a closed-loop system that is capable of supporting personalised recovery journeys.

The outcome; Nura, is a more engaging and accessible rehabilitation experience, designed and evaluated through the participation of stroke survivors.  It features a comfortable sleeve with embedded fabric electrodes and a detachable “puck” that delivers FES to the arm muscles to aid in rehabilitation. The device is controlled by a companion tablet app that provides gamified exercises to motivate users and features simple, one-touch controls for FES intensity adjustment.

Key Features: 

Wearable Sleeve: A comfortable sleeve with fabric electrodes that are integrated directly into the fabric, avoiding skin irritation.

“Puck” Controller: A detachable electronic component that houses the technology, including the microcontroller, which delivers the FES to the arm.

Gamified Rehabilitation: The device works with a tablet or Virtual Reality (VR) application, offering gamified exercises to enhance user engagement and motivation during rehabilitation.

Functional Electrical Stimulation (FES): Nura uses FES to stimulate arm muscles for wrist extension, ulnar, and radial deviation, helping to prevent muscle wastage.

User-Friendly Controls: The system allows for one-touch adjustment of FES intensity through the companion app, making it intuitive to use.

Biomedical Integration: The technology incorporates electromyography (EMG) sensors, which measure electrical activity in the muscles, and is designed to be integrated with existing rehabilitation and healthcare systems.

Targeted Audience: The Nura FES device is developed with stroke survivors in mind, especially those with cognitive impairments, providing a user-friendly and engaging way to regain strength and function.

According to a recent analysis from the @OfficeForNationalStatistics, the average stroke survivor loses £18,785 in earnings over a five year period, from the moment of their diagnosis. This is more than:

▪️Cancer
▪️Heart failure
▪️Heart attack
▪️Chronic kidney disease
▪️Diabetes
▪️Respiratory conditions
▪️Musculoskeletal conditions

From these conditions, stroke survivors were also least able to stay in permanent employment, four years after their diagnosis. This is clear evidence that more needs to be done to provide financial security for stroke survivors and their families, and yet the current Government insists on making it more difficult for people living with disabilities and long-term health conditions to access benefits like Personal Independence Payment (PIP).

We already know how difficult stroke survivors find the process of applying for PIP, and how many people are unsuccessful. If the Government continues with its current plan to introduce stricter measures and barriers to PIP and financial support, more and more stroke survivors are going to be left with less and less.



We are on Facebook

ARNI